Analysis of polymorphisms (VKORC1c.-1639G>A, CYP2C9*2 and CYP2C9*3) affecting individual response to anticoagulant therapy

Medicine has always tried to fulfil long dream of adapting treatment to characteristics of each individual, but only modern genetics has succeeded in explaining what makes individuals specific in response to drugs. Variety of drugs is used for treatment of cardiovascular diseases and some of them are high on the list of severity of side effects.

We have selected a group of genes (VKORC1, CYP2C9) whose variations affect efficiency and side effects of coumarin derivatives (warfarin and acenocoumarol), which are the most widely prescribed drugs for the prevention and treatment of thromboembolic disorders.

The optimal period for testing is during VKA therapy planning (e.g. before heart valve replacement surgery). 

For genetic testing, it is necessary to deliver 2.5-5 ml of peripheral blood with sodium citrate as an anticoagulant.

For payment instructions, please contact us.


Ljiljana Rakicevic, PhD

Dragica Radojkovic, PhD

TEL: + 381 11 3976 658

MOB: + 381 65 3976 658

FAX: + 381 11 3975 808


Please publish modules in offcanvas position.